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Abstract Though pursuit of host genetic factors that
influence the pathogenesis of HIV began over two decades
ago, progress has been slow. Initial genome-level searches
for variations associated with HIV-related traits have
yielded interesting candidates, but less in the way of novel
pathways to be exploited for therapeutic targets. More
recent genome-wide association studies (GWAS) that
include different phenotypes, novel designs, and that have
examined different population characteristics suggest novel
targets and affirm the utility of additional searches. Recent
findings from these GWAS are reviewed, new directions for
research are identified, and the promise of systems biology
to yield novel insights is discussed.
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Introduction
Natural history cohort studies of HIV-1 were initiated in the
United States and Europe during the peak of the AIDS
epidemic (circa 1990). At the time, genome search methods
were limited to family-based approaches, relegating the
search for host genetic factors to candidate genes studies
informed by a limited understanding of the pathophysiol-
ogy of HIV [1￿￿]. Nonetheless, progress was made, and the
identification of the co-receptors for viral entry [2, 3]
quickly led to the identification of allelic variants of the
primary co-receptor, CCR5, that was depleted in HIV-1-
infected individuals [4] and the carriers of which displayed
delayed progression once infected with the virus. This key
discovery demonstrated that host genetic factors could
influence the course of HIV infection, provide insights into
mechanisms, and suggest therapeutic targets. For an
excellent review, the reader is directed to An and Winkler
[1￿￿].
The turn of the century brought new assay platforms and
analytic methodologies that would allow for whole genome
searches to be performed efficiently in unrelated individuals.
To date, 11 genome-wide searches of varying design have
been performed [5, 6, 7￿, 8–10, 11￿, 12–14]. While the
concordance among the genome-wide association study
(GWAS) findings is striking, these similarities are due in
part to the phenotypes and subgroups of individuals selected
for study.
GWAS of HIV Pathogenesis
The search for novel host genetic factors that influence HIV
pathogenesis has focused on a restricted and largely
overlapping set of phenotypes. These phenotypes have
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end points and measurements that are summarized below. It
follows that the susceptibility loci identified thus far
participate in innate and adaptive immunity. All of the
studies reviewed below are of high quality in terms of study
designs, genomic data collection, and data analysis.
Moreover, a compelling mechanistic rationale exists for
each gene identified.
HIV RNA viral load at set point refers to the acute phase
of the initial HIV infection when viral replication attains a
steady-state. Though challenging to define given the typical
follow-up period in most cohort studies (i.e., bi-annual
visits), and the exclusion of many HIV-infected individuals
who did not meet the inclusion criteria, the concordance
among findings from GWAS studies to date were striking
(Table 1). Specifically, three loci have mapped to the major
histocompatibility locus on chromosome 6 and have been
verified in every cohort examined for viral load set point to
date. Human leukocyte antigen (HLA) P5 (HCP5), HLA
class B (HLA-B), and HLA-C harbor protective alleles that
were associated with lower viral load at set point [6, 7￿, 13].
The high degree of correlation (termed linkage disequilibrium
[LD]) between HCP5 and HLA-B made their independent
associations with viral load at set point difficult to disentangle
due to the small number of cases with rare recombination
eventsbetween theseloci. However, the association originally
mapped to the HCP5 locus was subsequently dissected
[6, 15￿￿]. These analyses suggest that the HCP5 locus is
associated with higher viral load at set point and the HLA-B
locus (primarily HLA-B*57) is responsible for the protective
effects detected by the single nucleotide polymorphism
(SNP) located in HCP5 [15￿￿].
Disease progression, defined as the time from serocon-
version until the point at which immunosuppression occurs
(i.e., a CD4
+ T-cell count less than 350 cells/mm
3, initiation
of highly active antiretroviral therapy [HAART]), is a
clinical end point of considerable interest. The extremes of
the distribution in terms of disease progression, rapid
progressors (RP), and long-term non-progressors (LTNP)
have been the focus of several genome searches. Aside
from the associations previously identified with the related
phenotype, viral load at set point HCP5, HLA-B, HLA-C
and variation of the zinc ribbon domain containing 1
(ZNRD1) gene are associated with disease progression
[6, 7￿, 12].
Three studies that employed unique study designs are
described below that resulted in the identification of
additional novel disease loci for disease progression. The
first study sought to refine the LTNP phenotype by
excluding elite controllers. Elite controllers differ from
LTNPs in that they suppress RNA viral load at levels that
are below the limit of detection. Exclusion of elite
controllers in a GWAS for LTNP uncovered an additional
risk locus, C-X-C chemokine receptor type 6 (CXCR6),
validated in several cohorts [11￿]. The second study sought
to capture the entire spectrum of progression by initially
screening three subgroups (i.e., RP, moderate progressors,
LTNP), followed by replication in a larger cohort [8].
Variation in the prospero homeobox 1 (PROX1) gene was
associated with slower progression. The third study first
performed a two-stage linkage analysis in two family-based
cohorts of macaques, and replicated an association signal
detected on the X chromosome with viral load at set point
and disease progression in a cohort of HIV-infected
individuals [14]. The association signal mapped to an
intragenic SNP located between the gene encoding for
ribosomal protein S6 kinase alpha-6 (RPS6KA6) and the
gene encoding for cylicin-1 (CYLC1). Subsequent validation
in a larger sample may allow the gene underlying this
association to be definitively identified.
Whereas the association signals with LTNP show
considerable overlap with loci detected using disease
progression [6, 7￿, 8, 12] as the phenotype, analysis of RP
yielded unique loci [10] that have proven difficult to
replicate in other cohorts. This inability to replicate may
be due in part to the under-representation of RP in most
cohorts. However, the possibility that individuals who are
RP or LTNP harbor risk alleles that are unique to each tail
in the distribution cannot be discounted. The minor alleles
of SNP mapping to the gene-encoding protein arginine
methyltransferase 6 (PMRT6), the gene encoding the sex-
determining region Y-box 5 (SOX5) gene, and the gene
encoding for the transforming growth factor, beta receptor
associated protein 1 (TGFBRAP1) alleles were depleted in
RP. The risk allele mapping to the retinoid X receptor
gamma (RXRG) gene was enriched in RP.
The majority of genome searches performed to date have
focused on European-descent populations [5, 6, 7￿, 8, 10,
11￿, 12]. This approach is reasonable as it reflects the
demographic of the epidemic when the cohorts analyzed
thus far were initiated. The recent development of methods
to account for more complex population substructure has
paved the way to examination of populations with more
diverse ancestry, such as Africans [9] and African Americans
[13]. Although the first recently reported GWAS for viral
load set point in African Americans failed to identify risk
loci that exceeded the significance thresholds required of
genome-wide searches, the associations with HCP5 and
HLA-C were validated [13]. Examination of a completely
different phenotype, maternal-to-child transmission in a
cohort of HIV-serodiscordant children of HIV-infected
mothers from Malawi, yielded several positional candidate
genes. However, none exceeded the a priori significance
thresholds. Further examination of these suggestive associ-
ation signals may provide insights into the host genomic
influence of the vertical transmission of HIV. Both studies
Curr HIV/AIDS Rep (2011) 8:38–44 39Table 1 Genome-wide searches for HIV-related traits
Trait Sample description Locus information Associated effect Study
￿ Viral load set-point Caucasian seroconverters
a HCP5 (rs2395029) Protective (lower viral load set point) Fellay et al. [7￿],
2007
￿ Disease progression Initial GWAS: n=486 HLA-C (rs9264942) Protective (lower viral load set point)
Focused replication: n=140 ZNRD1 (rs3869068) Harmful (disease progression)
￿ Plasma viral load (RNA) Caucasian seroconverters
b HCP5 (rs2395029) Protective (lower RNA & DNA
viral load)
Dalmasso et al.
[5], 2008
￿ Cellular viral load (DNA) Initial GWAS: n=605 HLA-C (rs10484554) Harmful (higher RNA & DNA viral load)
Focused replication: n=45 DDX40/YPEL2 (rs6503919)
SDC2 (rs2575735)
Protective (lower RNA & DNA viral load)
Protective (lower RNA & DNA viral load)
￿ Long-term non-
progressors (LTNP)
Caucasian seroconverters
a, c HCP5 (rs2395029) Protective (enriched in LTNP, lower viral
load)
Limou et al. [12],
2009
Initial GWAS: n=275 HLA-C (rs10484554) Harmful (depleted in LTNP, higher viral
load)
Focused replication: n=626 ZNRD1 (rs8321) Protective (enriched in LTNP)
￿ Rapid progressors (RP) Caucasian seroconverters
a, c PRMT6 (rs4118325) Protective (depleted in RP) Le Clerc et al.
[10], 2009
Initial GWAS: 85 RP compared
to 275 LTNP
SOX5 (rs1522232) Protective (depleted in RP)
RXRG (rs10800098) Harmful (enriched in RP)
TGFBRAP1 (rs1020064) Protective (depleted in RP)
￿ Cellular susceptibility
to HIV
Caucasian seroconverters
d LY6 (rs2572886) Harmful (higher RNA viral load) Loeuillet et al.
[16], 2008
Initial GWAS: n=254 cell lines
Focused replication: n=805
￿ Viral load set-point Caucasian seroconverters
d, e HCP5/HLA-B-5701 (rs2395029) Protective (lower viral load set point,
slower progression)
Fellay et al. [6],
2009
￿ Disease progression Initial GWAS: n=1,397 HLA-C (rs9264942) Protective (lower viral load set point,
slower progression)
Focused replication: n=1,157
￿ Disease progression Caucasian seroconverters
a, h RPS6KA6/CYLC1 (rs5968255) Protective (slower progression) Siddiqui et al.
[14], 2009
Linkage scan: n=264 macaques
Focused replication: n=805
￿ Viral load set-point African American seroconverters
d, g [Failed to exceed significance
threshold]
N/A Pelak et al. [13],
2010
Initial GWAS: n=515
￿ LTNP, excluding elite
controllers
Caucasian seroconverters
c CXCR6 (rs2234358) Harmful (depleted allele in LTNP) Limou et al. [11￿],
2010
Initial GWAS: n=605 compared
to HIV- controls (n = 697)
Multiple replications: n=1,028
￿ Mother-to-child
transmission
African children [Failed to exceed significance
threshold]
N/A Joubert et al. [9],
2010
GWAS: 100 HIV+ compared to 136
HIV- children
￿ Disease progression Caucasian seroconverters
e, f PROX1 (rs17762192/rs1367951/
rs17762150)
Protective (slower progression) Herbeck et al. [8],
2010
Initial GWAS: n=156
Focused replication: n=590
aEuro-CHAVI consortium
bANRS PRIMO
cARNS Cohort
dSwiss HIV cohort
eMACS
fMixed
gDoD HIV NHS
hCHAVI consortium.
40 Curr HIV/AIDS Rep (2011) 8:38–44suggest that novel phenotypes may provide additional novel
genes that influence other facets of HIV transmission and
pathogenesis.
To date, two genome searches have pursued novel HIV
traits. The first involved examination of not only circulating
RNA viral load, but viral DNA that serves as an estimate of
the HIV viral reservoir [5]. In addition to the verification of
the previous associations with HCP5 and HLA-C, two
additional associations with both lower RNA and DNA
viral load were identified. The first was in the syndecan 2
(SYND2) and the second was with an intragenic SNP that
detected two flanking positional candidate genes: DEAH
(Asp-Glu-Ala-His) box polypeptide 40 (DDX40) and the
human homolog of yippee-like 2 (YPEL2) [16]. Future
validation efforts may be able to identify which of the two
genes (DDX40 or YPEL2) underlies this later association
signal.
Opportunities for Future Research
Although the discoveries made thus far using genome-wide
searches are clear, many opportunities remain for additional
discoveries. Perhaps the most pragmatic opportunity lies in
the secondary analysis of the currently available GWAS
data. Three analytic methods are likely to yield additional
insights:meta-analysis,focusedgene–geneinteractions(i.e.,a
specific type of gene–gene interaction termed epistasis), and
pathwayanalysis[17]. Locus-specific meta-analyses [12], the
examination of specific gene–gene interactions [6], and
pathway analysis performed by Fellay and colleagues [6]
have been pursued in a subset of the GWAS described. The
availability of several new and imminent GWAS datasets
suggests that a more in-depth series of analyses are possible.
These types of analyses may uncover additional genetic
associations that could not surpass the statistical significance
thresholds in the component studies due to limited power.
The GWAS reported to date have focused primarily on
European-descent male populations that reflect the demo-
graphics of the AIDS epidemic at the time that natural
history cohorts were built. Whereas considerable value
exists in studying these cohorts, the demographics of HIV
disease have shifted. Women of color are at highest risk for
new infection. Cohorts that represent this shift in demograph-
ics(i.e.,non-Europeandescent,women),suchastheWomen’s
Interagency HIV Study (WIHS) [18], are currently available.
The examination of gender-specific or gender-modified
genetic associations was observed for two of the novel loci
discovered by GWAS to date [12, 14]. In addition, the
emergence of natural history cohorts of HIV in non-
European-descent populations, such as the Centre for the
AIDS Programme of Research in South Africa (CAPRISA)
[19], will allow for the examination of the influence of
different HIV subtypes in the genetic associations identified
to date and that may result in the identification of novel
associations. An important caveat to GWAS in populations
of non-European descent is that genetic marker coverage in
the current commercially available arrays is variable. This
limitation was in evidence in the study of Loeuillet and
colleagues, where a key risk allele was not tagged in a
commonly used commercial array for genome-wide variation
measurement [16]. Fortunately, the goal of the 1000
Genomes Project (1KGP, www.1000genomes.org)i st o
dramatically expand the catalog of variation for the next
generation of GWAS search tools, with the goal of
identifying nearly all variants that exist at any appreciable
frequency in human populations.
Recent advances in DNA resequencing have revolution-
ized the fields of genetics and genomics. Without doubt,
whole genome sequencing will eventually supersede the
current GWAS approach (i.e., measuring relatively common
sequence variations). The barriers to the application of this
genome search tool by research groups of even modest
resources include the cost, error profiles, and limitations of
the new sequencing platforms that differ from traditional
sequencing technologies, and foremost are the bioinfor-
matic challenges (for a review see [20, 21]). However, deep
re-sequencing of candidate gene regions with high prior
index of suspicion, such as those identified in multiple
independent GWAS and supported by functional studies, is
a method that is currently tenable and suffers more
modestly from the barriers identified above. This method
currently serves as a powerful adjunct to GWAS and is
useful in the identification of rare variants and/or sequence
anomalies not currently captured in commercially available
genotyping arrays [22].
The greatest frontier for the discovery of host genetic
factors that influence the pathogenesis of HIV lies ahead.
To date, the genome searches have focused primarily on
plasma RNA viral load and disease progression as
estimated by peripheral blood CD4+ T-cell count. Though
the concordance of the findings has affirmed the value of
studying these traits and outcomes, the genes that these
phenotypes have implicated play a primary role in either
innate and/or adaptive immunity. The utility of examination
of novel phenotypes, including in vitro characterization, is
evident [16]. Recent advances in the understanding of the
molecular mechanisms of HIV proviral latency [23] may
inform the selection of future phenotypic analyses. The
longitudinal data accrued in most natural history cohorts to
date are limited by participant burden and cost, with bi-annual
visits being the most common time-interval. However, the
modeling of more complex patterns of change over time [24]
(e.g., J-shape curves for viral load following acute infection,
CD4+ T-cell count decline trajectories, latent variable
analysis) may provide phenotypes that are superior to those
Curr HIV/AIDS Rep (2011) 8:38–44 41examined to date. The availability of banked serial biological
specimens in many cohorts for which GWAS were reported
suggests that cost effective studies can be performed by the
addition of novel phenotypes that can be coupled with
currently available genome-wide genetic marker data.
The emergence of HAART has naturally led to the
examination of phenotypes captured prior to HAART due
to the considerable complexity and ongoing evolution of
these therapies in terms of drug targets. However,
variable responses to HAART as well as differences in
adverse event profiles remain a fundamental barrier to
the success of these treatments [25]. Recent identification
of gene polymorphisms that predict hypersensitivity
reactions to different HAART drugs suggests that this line
of inquiry is tenable [25]. The recent development of
resource-efficient drug exposure measures, such as the
measurement of HAART deposition in hair, holds promise
to provide additional insights into pharmacogenomic risk
factors as confounding due to self-report adherence is
largely circumvented [26–28].
GWAS of HIV-Associated Comorbid Disease
With the advent of HAART, HIV infection transitioned
from an acute to a chronic disease. It is now well accepted
that chronic HIV infection and/or HAART may influence
several co-morbid diseases of aging as well as elicit disease-
specificconditions[29, 30]. These conditions include, but are
not limited to, neuropathy [31], nephropathy, atherosclerosis
[32], metabolic perturbations [33], and neurocognitive
disorders [34￿]. In addition, the role of the host genome in
the setting of co-infections that are common in HIV-infected
individuals (e.g., hepatitis C, human papilloma virus) is an
active area of research, particularly given the increased risk
for common co-morbid disease (e.g., chronic kidney disease
[35]).
The complex and poorly understood natural history of
HIV infection necessitated rigorous longitudinal follow-up
and in-depth characterization of the participants (e.g.,
demographic characteristics, clinical characteristics, co-
morbid diseases, cell repository) enrolled into natural
history cohorts. A natural byproduct of these intense and
sustained studies is the possibility to not only contribute to
an understanding of HIV and subsequently response to
HAART, but also common co-morbid disorders and
diseases. Below, two GWAS that serve as compelling
exemplars of the importance of studying comorbid diseases
in the setting of HIV are described.
Risk for chronic kidney disease is strikingly elevated in
the setting of HIV infection. In addition, differences by race
are observed with African Americans at increased risk.
Mapping by admixture linkage disequilibrium, a method
that detects ancestral risk alleles for disease in groups of
individuals from recently mixed populations, resulted in the
identification of a novel risk locus (i.e., myosin, heavy
chain 9, non-muscle [MYH9]) [36]. Although recent
evidence suggests that an adjacent locus may underlie the
association with the MYH9 locus [37], the power of the
approach is clear.
An equally promising discovery by GWAS of athero-
sclerosis in the setting of HIV was recently reported by
Shrestha and colleagues [38]. Their search resulted in the
identification of two SNPs in tight LD associated with
carotid intima-media thickness mapping to the ryanodine
receptor (RYR3). Previous work not only implicated a role
for these SNPs in the etiology of cardiovascular disease, but
the RYR3 protein is also known to interact with the HIV
Tat protein. Clearly, additional research is warranted to
better understand the role of the host genome in risk for
common disease within the context of HIV.
Systems Biology: A New Vista to Understanding HIV
Pathogenesis
Clearly, the complex host–viral interactions that underlie
HIV pathogenesis will not be unraveled by GWAS alone.
The integration of several other components of both cellular
and organism-level processes will be required, termed a
systems biology approach. Recent examinations of different
functional RNA (fRNA) classes and gene expression
profiles of specific host immune cell populations have
yielded unique insights into HIV infection [1￿￿]. The
examination and integration of genomic, epigenomic,
transciptomic, proteomic, metabolomic, and viral protein
interactome are requisite. Though bioinformatic, computa-
tional, and statistical barriers to the integration of these data
exist, new solutions to these challenges emerge daily. The
integration of these data is sure to suggest novel therapeutic
opportunities to interfere with the host–viral interaction to
stymie effective infection.
Conclusions
The success of GWAS in the identification of HIV infection
and control of viral levels (i.e., set point) is clear. However,
the genes discovered to date and their variations only
explain a portion of the variance in these traits. The
addition of novel phenotypes in cohorts with pre-existing
genome-wide data, the examination of novel cohorts by
GWAS, and the application of novel analytic approaches
and data mining will undoubtedly yield novel insights into
HIV pathogenesis and risk for common co-morbid diseases.
GWAS remains a cost-effective strategy to identify genes of
42 Curr HIV/AIDS Rep (2011) 8:38–44interest that can be the focus of more resource-intensive
functional and molecular studies. And finally, a systems
biology approach will permit the integration of GWAS
findings with other facets of cellular and organism-level
biology and to prioritize targets for future therapies.
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